{"entity":{"id":"nct06947928","kind":"trial","name":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car","aka":[],"tldr":"A phase 2/3 trial of Pembrolizumab in merkel cell carcinoma, run by TuHURA Biosciences, Inc., now recruiting.","summary":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma is a phase 2/3 interventional study registered as NCT06947928 by TuHURA Biosciences, Inc., with 118 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: IFx-Hu2.0, Placebo, Pembrolizumab. Conditions listed: Advanced Or Metastatic Merkel Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06947928","url":"https://clinicaltrials.gov/study/NCT06947928"}],"tags":["ctgov-ingest"],"related":[],"cancers":["merkel-cell-carcinoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06947928","phase":"2/3","setting":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma","sponsor":"TuHURA Biosciences, Inc.","participation":[{"nct":"NCT06947928","source":"https://clinicaltrials.gov/study/NCT06947928","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"1338978e82d32afe820eaffff19f1948e79b162535716f1c43a120529f2b97e9","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-17","leadSponsor":"TuHURA Biosciences, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":118,"enrolmentType":"ESTIMATED","siteCount":18,"recruitingSiteCount":18,"countries":["United States"]}],"started":"2025-12-11","startedType":"actual","enrolled":118,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06947928/","neighbours":{"cancer":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}